Alpenglow Biosciences builds a non-destructive 3D microscopy and AI platform (Aurora™) to move pathology from single slides to whole-tissue, 3D analysis. Its core products include research-use-only 3D Derm Score™ and 3D Immuno-Oncology (I‑O) Score™, which are available for clinical trials to support biopharma drug development. The company is advancing clinical product development with programs for intraoperative precision tumor removal and prostate cancer diagnostics. Recent awards and investment are being used to support FDA regulatory strategy and reimbursement planning through ARPA‑H’s PATIO program. Alpenglow partners with academic labs and clinical centers (including the Liu Biophotonics Lab at UW, Mahmood AI Lab at Harvard & Mass General Brigham, Vanderbilt University Medical Center, and CorePlus) to validate and deploy its assays. Founded in 2018 and based in Seattle, the company says its platform offers superior predictive power versus slide-based digital pathology when combined with its AI algorithms. Lightspeed Microscopy develops an end-to-end 3D pathology platform combining novel chemistry, a patented open-top light-sheet microscope, and cloud-based AI for non-destructive imaging of large tissues at sub-cellular resolution. The solution encompasses tissue labeling, tissue clearing, high-throughput imaging, cloud processing, and 3D digital analysis. The company intends to use recent financing to commercialize and scale its microscopy platform. Lightspeed was spun out of the University of Washington and is led by CEO Nicholas Reder, MD, MPH. The platform targets pathology workflows that require volumetric, high-resolution tissue imaging.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2024